laurabbook@gmail.com

*April 2023* The discussion then shifted to liquid and tissue biopsies. Liquid biopsies, which involve looking for abnormal DNA in the blood, are described as a great tool for patients whose tumors are shedding into their bloodstream. However, a negative result does not necessarily mean that there's no mutation, as…

*June 2023* Purpose:The uncommon EGFR exon 19 deletion (ex19del), L747_A750>P, demonstrates reduced sensitivity to osimertinib compared with the common ex19del, E746_A750del in preclinical models. The clinical efficacy of osimertinib in patients with non–small cell lung cancer harboring L747_A750>P and other uncommon ex19dels is not known. Design:The AACR GENIE database was interrogated to…

*April 2023* A complete understanding of how exposure to environmental substances promotes cancer formation is lacking. More than 70 years ago, tumorigenesis was proposed to occur in a two-step process: an initiating step that induces mutations in healthy cells, followed by a promoter step that triggers cancer development1. Here we propose…

*April 2023* Circulating tumor DNA (ctDNA) analysis can identify patients with residual disease before it is clinically or radiologically evident. Minimal residual disease (MRD) is an advancing area in the management of radically treated solid tumors. Which MRD assay is optimum and when it should be used is still not…

*March 2023* Note: Histological transformation from NSCLC to SCLC can occur as a resistance mechanism to EGFR TKIs. The presence of PTEN with RB1/TP53 loss/deletion may contribute to this transformation. Introduction High-grade neuroendocrine tumors of the lung such as SCLC are recalcitrant cancers for which more effective systemic therapies are needed.…

*June 2022* Biomarker testing, which may also be called molecular testing or tumor marker testing, is when doctors perform detailed studies on tumor tissue taken during a biopsy or blood sample to understand the specific features of a person's cancer. Biomarkers are substances found in higher-than-normal levels in the blood, urine, or tissues…

*March 2023* Highlights: Lazertinib showed comparable efficacy and safety in real-world clinical settings. Lazertinib demonstrated durable disease control both systematic and intracranially. The most common adverse event was paresthesia which was manageable by dose modification. Further development of lazertinib in 1st line is highly warranted. Read more.

The presentations in this on-demand event include the following (You will have to create an account to view):  Best Practices for Molecular Testing in Advanced NSCLC and Decoding NGS Reports How much do you know about optimal molecular testing methods for patients with advanced NSCLC? Dara L. Aisner, MD, PhD…

*March 2023* Results: Fifty patients were allocated to the control group, and 46 were allocated to the experimental group (NTG); among these, 26 (52%) had EGFRm in the control group and 21 (45.7%) had EGFRm in the NTG arm. In terms of the iORR, patients in the NTG group had a…